CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...